Literature DB >> 24438954

Point: Major adverse cardiovascular events and anti-IL 12/23 agents.

Thrasivoulos Tzellos1, Athanassios Kyrgidis1, Anastasia Trigoni2, Christos C Zouboulis3.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24438954     DOI： 10.1016/j.jaad.2013.07.050

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  4 in total

Review 1.  Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows.

Authors:  Giuseppina Caiazzo; Gabriella Fabbrocini; Roberta Di Caprio; Annunziata Raimondo; Emanuele Scala; Nicola Balato; Anna Balato
Journal:  Front Immunol       Date:  2018-08-13       Impact factor: 7.561

2.  Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients.

Authors:  Marthe-Lisa Schaarschmidt; Christian Kromer; Raphael Herr; Astrid Schmieder; Diana Sonntag; Sergij Goerdt; Wiebke K Peitsch
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

3.  Heptapeptide HP3 acts as a potent inhibitor of experimental imiquimod‑induced murine psoriasis and impedes the trans‑endothelial migration of mononuclear cells.

Authors:  Ernesto A Vázquez-Sánchez; José S Mendoza-Figueroa; Guadalupe Gutiérrez-Gonzalez; Luis A Zapi-Colín; Azael Torales-Cardeña; Paola E Briseño-Lugo; Iván Díaz-Toalá; Juan C Cancino-Diaz; Sonia M Pérez-Tapia; Mario E Cancino-Diaz; Fernando Gómez-Chávez; Sandra Rodríguez-Martínez
Journal:  Mol Med Rep       Date:  2020-05-05       Impact factor: 2.952

Review 4.  The Risk of Systemic Diseases in Those with Psoriasis and Psoriatic Arthritis: From Mechanisms to Clinic.

Authors:  Yu Ri Woo; Chul Jong Park; Hoon Kang; Jung Eun Kim
Journal:  Int J Mol Sci       Date:  2020-09-24       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.